Top

Published in:

01-02-2013 | Original Communication

Supporting evidence for using biomarkers in the diagnosis of MCI due to AD

Authors: Samantha Galluzzi, Cristina Geroldi, Giovanni Amicucci, Luisella Bocchio-Chiavetto, Matteo Bonetti, Cristian Bonvicini, Maria Cotelli, Roberta Ghidoni, Barbara Paghera, Orazio Zanetti, Giovanni B. Frisoni, Translational Outpatient Memory Clinic Working Group

Published in: Journal of Neurology | Issue 2/2013

Abstract

The aim of this study is to support the use of biomarkers in the diagnosis of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) according to the revised NIA-AA diagnostic criteria. We compared clinical features and conversion to AD and other dementias among groups of MCI patients with different abnormal biomarker profiles. In this study, we enrolled 58 patients with MCI, and for each of them AD biomarkers (CSF Abeta42 and tau, temporoparietal hypometabolism on 18F-FDG PET, and hippocampal volume) were collected. Patients were divided into three groups: (i) no abnormal biomarker, (ii) AD biomarker pattern (including three subgroups of early = only abnormal Abeta42, intermediate = abnormal Abeta42 and FDG PET or tau, and late = abnormal Abeta42, FDG PET or tau, and HV), and (iii) any other biomarker combination. MCI patients with AD biomarker pattern had lower behavioural disturbances than patients with any other biomarker combination (p < 0.0005). This group also showed lower performance on verbal and non-verbal memory than the other two groups (p = 0.07 and p = 0.004, respectively). Within the three subgroups with AD biomarker patterns we observed a significant trend toward a higher rate of conversion to dementia (p for trend = 0.006). With regard to dementia conversion, 100 % of patients with an AD biomarker pattern developed AD, but none of the patients with no abnormal biomarker and 27 % of patients with any other biomarker combination (p = 0.002) did so. We also described some clinical cases representative for each of these three groups. The results of this study provide evidence in favour of the use of biomarkers for the diagnosis of MCI due to AD, in line with recently published research criteria.

Available only for authorised users

Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:270–279PubMedCrossRef

American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, USA

Arai H, Terajima M, Miura M et al (1995) Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer’s disease. Ann Neurol 38:649–652PubMedCrossRef

Bennett DA, Wilson RS, Schneider JA et al (2002) Natural history of mild cognitive impairment in older persons. Neurology 59:198–205PubMedCrossRef

Bian H, Van Swieten JC, Leight S et al (2008) CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 70:1827–1835PubMedCrossRef

Bibl M, Mollenhauer B, Lewczuk P et al (2011) Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias. Dement Geriatr Cogn Disord 31:37–44PubMedCrossRef

Braak H, Braak E (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18:351–357PubMedCrossRef

Braak H, Del Tredici K (2011) The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta Neuropathol 121:171–181PubMedCrossRef

Caroli A, Prestia A, Chen K, EADC-PET Consortium, NEST-DD, and Alzheimer’s Disease Neuroimaging Initiative et al (2012) Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. J Nucl Med 53:592–600PubMedCrossRef

10.

Clark CM, Xie S, Chittams J et al (2003) Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 60:1696–1702PubMedCrossRef

11.

Cummings JL, Mega M, Gray K et al (1994) The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44:2308–2314PubMedCrossRef

12.

De Leo D, Frisoni GB, Rozzini R, Trabucchi M (1993) Italian community norms for the brief symptom inventory in the elderly. Br J Clin Psychol 32:209–213PubMedCrossRef

13.

De Souza LC, Lamari F, Belliard S et al (2012) Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer’s disease from other cortical dementias. J Neurol Neurosurg Psychiatry 82:240–246CrossRef

14.

Edison P, Rowe CC, Rinne JO et al (2008) Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C] PIB positron emission tomography. J Neurol Neurosurg Psychiatry 79:1331–1338PubMedCrossRef

15.

Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198PubMedCrossRef

16.

Frisoni GB, Pievani M, Testa C et al (2007) The topography of grey matter involvement in early and late onset Alzheimer’s disease. Brain 130:720–730PubMedCrossRef

17.

Frisoni GB, Prestia A, Zanetti O et al (2009) Markers of Alzheimer’s disease in a population attending a memory clinic. Alzheimers Dement 5:307–317PubMedCrossRef

18.

Galluzzi S, Geroldi C, Ghidoni R et al (2010) The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment. J Neurol 257:2004–2014PubMedCrossRef

19.

Galluzzi S, Testa C, Boccardi M et al (2009) The Italian brain normative archive of structural MR scans: norms for medial temporal atrophy and white matter lesions. Aging Clin Exp Res 21:266–276PubMed

20.

Ghidoni R, Benussi L, Paterlini A et al (2011) Cerebrospinal fluid biomarkers for Alzheimer’s disease: the present and the future. Neurodegener Dis 8:413–420PubMedCrossRef

21.

Ghidoni R, Paterlini A, Albertini V et al (2011) A window into the heterogeneity of human cerebrospinal fluid Aβ peptides. J Biomed Biotechnol 2011:697036PubMedCrossRef

22.

Hampel H, Burger K, Teipel SJ et al (2008) Core candidate neurochemical and imaging biomarkers of Alzheimer’s disease. Alzheimers Dement 4:38–48PubMedCrossRef

23.

Herholz K, Salmon E, Perani D et al (2002) Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 17:302–316PubMedCrossRef

24.

Hoffman JM, Welsh-Bohmer KA, Hanson M et al (2000) FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 41:1920–1928PubMed

25.

Ingelsson M, Fukumoto H, Newell KL et al (2004) Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62:925–931PubMedCrossRef

26.

Jack CR Jr, Petersen RC, Xu Y et al (2000) Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 55:484–489PubMedCrossRef

27.

Jack CR Jr, Lowe VJ, Weigand SD, Alzheimer’s Disease Neuroimaging Initiative et al (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain 132:1355–1365PubMedCrossRef

28.

Jack CR Jr, Knopman DS, Jagust WJ et al (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 9:119–128PubMedCrossRef

29.

Lawton MP, Brody EM (1969) Assessment of older people: self maintaining and instrumental activities of daily living. Gerontologist 9:179–186PubMedCrossRef

30.

Lezak M, Howieson D, Loring DW (2004) Neuropsychological assessment, 4th edn. University Press, Oxford

31.

Mayeux R, Small SA, Tang M et al (2001) Memory performance in healthy elderly without Alzheimer’s disease: effects of time and apolipoprotein-E. Neurobiol Aging 22:683–689PubMedCrossRef

32.

McKeith IG, Galasko D, Kosaka K et al (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113–1124PubMedCrossRef

33.

McKhann G, Drachman D, Folstein M et al (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology 34:939–944PubMedCrossRef

34.

McKhann GM, Albert MS, Grossman M et al (2001) Work group on frontotemporal dementia and pick’s disease clinical and pathological diagnosis of frontotemporal dementia: report of the work group on frontotemporal dementia and pick’s disease. Arch Neurol 58:1803–1809PubMedCrossRef

35.

McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269PubMedCrossRef

36.

Seelaar H, Rohrer JD, Pijnenburg YA et al (2011) Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry 82:476–486PubMedCrossRef

37.

Sjogren M, Vanderstichele H, Agren H et al (2001) Tau and Abeta42 in cerebrospinal fluid from healthy adults 21–93 years of age: establishment of reference values. Clin Chem 47:1776–1781PubMed

38.

Strozyk D, Blennow K, White LR et al (2003) CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60:652–656PubMedCrossRef

39.

Wahlund LO, Barkhof F, Fazekas F et al (2001) European task force on age-related white matter changes. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 32:1318–1322PubMedCrossRef

40.

Whitwell JL, Wiste HJ, Weigand SD, for the Alzheimer Disease Neuroimaging Initiative et al (2012) Comparison of imaging biomarkers in the Alzheimer disease neuroimaging initiative and the mayo clinic study of aging. Arch Neurol 69:614–622PubMedCrossRef

41.

Womack KB, Diaz-Arrastia R, Aizenstein HJ et al (2011) Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors. Arch Neurol 68:329–337PubMedCrossRef

Title: Supporting evidence for using biomarkers in the diagnosis of MCI due to AD
Authors: Samantha Galluzzi
Cristina Geroldi
Giovanni Amicucci
Luisella Bocchio-Chiavetto
Matteo Bonetti
Cristian Bonvicini
Maria Cotelli
Roberta Ghidoni
Barbara Paghera
Orazio Zanetti
Giovanni B. Frisoni
Translational Outpatient Memory Clinic Working Group
Publication date: 01-02-2013
Publisher: Springer-Verlag
Published in: Journal of Neurology / Issue 2/2013
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-012-6694-0

At a glance: The STEP trials

Springer Medicine

Supporting evidence for using biomarkers in the diagnosis of MCI due to AD

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

A randomized controlled trial of intranasal-midazolam versus intravenous-diazepam for acute childhood seizures

Effects of dalfampridine on attacks in patients with episodic ataxia type 2: an observational study

Role of magnetic resonance imaging, cerebrospinal fluid, and electroencephalogram in diagnosis of sporadic Creutzfeldt-Jakob disease

Steroid-responsive hearing impairment in NMO-IgG/aquaporin-4-antibody-positive neuromyelitis optica

Cognitive and affective theory of mind in patients with essential tremor

Down on heights? One in three has visual height intolerance